



Editas Medicine Announces Departure of Chief Operating Officer

March 3, 2017

CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its Chief Operating Officer, Alexandra Glucksmann, Ph.D., will be leaving the Company, effective March 31. Dr. Glucksmann's responsibilities will be reallocated among current members of the Company's management team.

"On behalf of the entire Editas team, I sincerely thank Sandra for her countless contributions since the company's inception," said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. "As one of our founding employees, Sandra has been instrumental in helping launch our company and organize us around our mission of harnessing the potential of CRISPR genome editing to develop transformative medicines for patients. We wish Sandra the best in her future endeavors and will miss her leadership and dedication."

"Over the last three years, I have had the distinct privilege of working alongside some of the brightest and most thoughtful people in the industry," said Dr. Glucksmann. "While stepping away was not an easy decision, I do so with great confidence in Katrine and the entire team at Editas Medicine, as well as the future success of the company. I thank everyone for making my time here so special, and look forward to following the organization's continued success in the future."

Dr. Glucksmann joined Editas Medicine in 2013 as the first employee and Chief Operating Officer. Over the years, she has been responsible for managing the Company's daily operations as well as developing Editas Medicine's early pipeline strategy and business growth strategies.

About Editas Medicine

Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Forward Looking Statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact

Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com

Editas Investor Contact

Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com



Editas Medicine